Speaker's Profile

Thomas Tillett

MBF Therapeutics


Thomas Tillett – Cofounder and CEO of MBF Therapeutics, a life science company, is developing innovative gene-based check point inhibitor and immunomodulating immunotherapies to treat cancer and infectious diseases in both animals and humans. Tom is the founder and Executive Director of Sustained Acts, a non-profit organisation, and serves on the Friends of Kijabe Hospital Board of Directors. He was founder, and CEO of RHeoGene where he and his team created the RheoSwitch® Therapeutic System (RTS) that led to the first human clinical trial of a small molecule-induced gene regulation system.

In 2007, Thomas successfully completed the merger of RheoGene Inc. with Intrexon Corporation who has continued the development of RTS through a various clinical trial for cancer and other important therapeutic indications. In April 2019, the FDA announced that the RheoSwitch Therapeutic System for glioma blastoma was approved for Fast Track designation.

Quick Proposal

Get In Touch

Subscribe for updates:

Back to Top